Leveraging our expertise in TRPC5 biology and chemistry, we are developing follow-on compounds to our lead precision medicine product candidate, GFB-887, with differentiating attributes intended for broad market indications, such as DN. We believe that our novel structural insights enhance our understanding of TRPC5 inhibitor binding with TRPC channels, which will enable us to design desirable compounds more efficiently and accelerate our path to IND. Patients with DN are typically treated with a combination of multiple drugs and the compounds that we have discovered to date are being optimized to reduce risk of drug-to-drug interactions with the major drug classes used to treat diabetes. Additionally, we aim to design new compounds that are restricted to peripheral tissues. Molecules from our lead series have been observed in preclinical studies to be highly potent, metabolically stable, and, like GFB-887, orally available.